CRC Research Update — August 03, 2026
Today's colorectal cancer research highlights
Alex Chompff
Stool DNA Tests Offer Higher Sensitivity but Lower Specificity Than FIT
Skip to content
The CRC Digest
Stool DNA Tests Offer Higher Sensitivity but Lower Specificity Than FIT
Multitarget stool DNA tests show higher sensitivity for colorectal cancer and advanced adenomas than FIT, but with lower specificity and higher costs; further evidence is needed on long-term effectiveness and economic sustainability. (Clinical
Symptom Identification Critical for Adults 18-44
Skip to content
The CRC Digest
Symptom Identification Critical for Adults 18-44
Adults under 45 without access to average-risk screening require a well-defined system for symptom identification and workup to avoid diagnostic delays and worse outcomes. (Cancer Epidemiology, Biomarkers & Prevention)
This content is informational only and does not constitute
FIT Remains Cornerstone of Population-Based CRC Screening
Skip to content
The CRC Digest
▪ SCREENING
FIT Remains Cornerstone of Population-Based CRC Screening
Fecal immunochemical testing (FIT) continues to be the foundation of organized colorectal cancer screening programs due to its noninvasive nature, affordability, and proven mortality reduction, though stool DNA tests may serve as complementary options in hybrid
Study Examines Symptoms as Diagnostic Indicators in Adults Under 45
Skip to content
The CRC Digest
▪ SCREENING
Study Examines Symptoms as Diagnostic Indicators in Adults Under 45
(Cancer Epidemiology, Biomarkers & Prevention)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care team.
© 2026 The CRC Digest —
crcdigest.com
ctDNA Tracking May Guide Adjuvant Chemotherapy After Liver Metastasis Surgery
Skip to content
The CRC Digest
◆ TRIAL DATA
ctDNA Tracking May Guide Adjuvant Chemotherapy After Liver Metastasis Surgery
The phase II GALAXY study showed that circulating tumor DNA monitoring for molecular residual disease could help identify which patients with colorectal cancer liver metastases are most likely to benefit from chemotherapy
Circulating Tumor DNA Predicts Recurrence Risk in Stage III Colorectal Cancer
Skip to content
The CRC Digest
◇ RESEARCH
Circulating Tumor DNA Predicts Recurrence Risk in Stage III Colorectal Cancer
A systematic review and meta-analysis found that circulating tumor DNA (ctDNA) testing can help predict which stage III colorectal cancer patients are at higher risk of recurrence after surgery. (Clinical Colorectal Cancer)
CRC Research Update — August 02, 2026
Today's colorectal cancer research highlights
Evidence-Based Physical Activity Program Developed for Inactive CRC Survivors
Skip to content
The CRC Digest
Evidence-Based Physical Activity Program Developed for Inactive CRC Survivors
Researchers used a Delphi process with 15 experts to develop a comprehensive physical activity promotion intervention for colorectal cancer survivors who do not meet recommended activity levels. (Asia-Pacific Journal of Oncology Nursing)
This content is
Liquid Biopsy Detects ctDNA in 95% of Metastatic CRC Patients
Skip to content
The CRC Digest
▸ TREATMENT
Liquid Biopsy Detects ctDNA in 95% of Metastatic CRC Patients
A Japanese single-center study using Guardant360 CDx found circulating tumor DNA in 18 of 19 metastatic colorectal cancer patients, with a median turnaround time of 11 days and pathogenic alterations identified in 79%